仿制药品立法规制的发展新态势——以TPP医药专利条款为视角

发布时间：2018-01-18 11:04

本文关键词：仿制药品立法规制的发展新态势——以TPP医药专利条款为视角　出处：《荆楚理工学院学报》2016年03期 　论文类型：期刊论文

【摘要】：近几年,随着国外专利药的纷纷到期,各国都在为发展仿制药、抢占医药市场做好准备。以美国为主导的TPP谈判,在其高标准的知识产权条款中,对医药专利条款严格规定,试图抑制仿制药的发展,但是美国国内却对仿制药的发展进行立法保护。对TPP医药专利条款的内容加以分析,并对美国国内仿制药规制体系、具有特色的仿制药发展模式的印度立法进行介绍,结合二者的优点,并根据我国国情,对我国医药专利立法的完善提出建议,为今后我国医药市场的发展提供良好的立法环境,并对未来仿制药立法规制趋势进行展望。
[Abstract]:In recent years, with the expiration of foreign patent drugs, countries are preparing to develop generic drugs and seize the pharmaceutical market. The United States-led TPP negotiations are in its high standard terms of intellectual property rights. In order to restrain the development of generic drugs, the development of generic drugs is strictly regulated, but the development of generic drugs is protected by legislation in the United States. The contents of the patent provisions of TPP are analyzed. And the domestic generic drug regulatory system, with the characteristics of generic drug development model of Indian legislation were introduced, combined with the advantages of the two, and according to the national conditions of our country, put forward some suggestions for the perfection of Chinese pharmaceutical patent legislation. It provides a good legislative environment for the future development of pharmaceutical market in China, and looks forward to the trend of legislation regulation of generic drugs in the future.
【作者单位】：安徽财经大学法学院;
【分类号】：D997.1;D922.16;D923.42
【正文快照】： 近年来,由于多哈谈判的停滞不前,导致美国在投资、服务贸易、知识产权等多方面的诉求得不到满足,为了促进本国经济的发展和重夺其在亚太地区的主导地位,美国积极推动《跨太平洋伙伴关系协议》(Trans-Pacific Partnership Agreement,TPP)的谈判。TPP的谈判目前已基本达成一致,

【相似文献】